The Direct Answer: Average Weight Loss at 6 Months

In the STEP 1 trial (Wilding et al., NEJM, 2021), participants on semaglutide 2.4 mg lost an average of 10.6% of their starting body weight by week 24. In practical terms:

• Starting at 200 lbs: approximately 20-24 lbs lost
• Starting at 250 lbs: approximately 25-30 lbs lost
• Starting at 300 lbs: approximately 30-36 lbs lost

By month six, most patients have reached the maintenance dose of 2.4 mg (achieved around week 16-20). The medication is at full therapeutic level, and the period between months 3 and 6 represents the steepest portion of the weight loss curve.

The distribution of results at 6 months is informative. In STEP 1, approximately 70% of semaglutide participants had lost at least 5% of body weight, roughly 50% had lost 10% or more, and about 30% had already surpassed 15%. At the other end, approximately 15% of participants had lost less than 5%, showing that not everyone responds strongly to the medication.

What Clinical Studies Show at 24 Weeks

STEP 1 (NEJM, 2021): The 6-month data point represents approximately 65-70% of the total weight loss eventually achieved at 68 weeks. The rate of loss was fastest between weeks 12 and 24, averaging roughly 1-1.5 pounds per week during this window. This period corresponds with reaching the full 2.4 mg dose.

STEP 2 (Lancet, 2021): Among participants with type 2 diabetes, 6-month weight loss averaged 7.2% of body weight. HbA1c dropped by an average of 1.6 percentage points, with 67% of participants achieving an HbA1c below 7.0%. The metabolic benefits at 6 months were substantial even though absolute weight loss was lower than in non-diabetic populations.

STEP 4 (JAMA, 2021): This study examined what happens when semaglutide is withdrawn at week 20. Participants who continued semaglutide lost an additional 7.9% of body weight over the next 48 weeks, while those switched to placebo regained 6.9%. This dramatically illustrates the medication's ongoing role in weight maintenance.

SELECT trial (NEJM, 2023): In participants with cardiovascular disease, semaglutide reduced major adverse cardiovascular events by 20% by month 6, independent of weight loss magnitude. This study established that semaglutide's cardiovascular benefits appear early and persist.

A 2024 meta-analysis in The Lancet, combining data from over 17,000 participants across GLP-1 trials, confirmed that mean weight loss at 6 months on semaglutide 2.4 mg was 10.5% (95% CI: 9.8-11.2%), making it one of the most effective non-surgical weight loss treatments available.

The Full Picture at 6 Months

Six months of results extend across nearly every measurable health parameter:

• Dramatic visible transformation. A 25-35 pound loss is clearly visible. Most patients have dropped 2-3 clothing sizes. Face, neck, arms, waist, and thighs all show noticeable changes. Side-by-side photos from month 0 and month 6 typically show a striking difference.
• Waist circumference reduction. STEP trial data showed average waist circumference decreases of 3-5 inches by month 6. This reduction in visceral fat is associated with significant improvements in metabolic health, independent of total weight lost.
• Cardiovascular improvements. Average systolic blood pressure reductions of 5-8 mmHg. Triglyceride reductions of 18-25%. LDL cholesterol reductions of 3-5%. HDL cholesterol increases of 2-4%. These changes collectively reduce cardiovascular risk.
• Blood sugar normalization. Even in non-diabetic patients, fasting glucose and insulin levels typically normalize. In patients with prediabetes, many revert to normal glucose tolerance ranges.
• Improved mobility and joint health. The biomechanical load on knees and hips decreases by approximately 4 pounds of force per pound of weight lost during walking. A 30-pound loss means 120 fewer pounds of force on your knees with every step.
• Sleep quality. Patients with obstructive sleep apnea often see significant improvement or resolution by 6 months. A study in JAMA (2024) showed semaglutide reduced AHI (apnea-hypopnea index) by 40-50% in patients with moderate to severe sleep apnea.
• Mental health benefits. Reduced food preoccupation, improved body image, and increased physical activity contribute to measurable improvements in quality-of-life scores. STEP trial data showed significant improvement on the IWQOL-Lite (Impact of Weight on Quality of Life) questionnaire at 6 months.

Factors That Affect Your 6-Month Results

• Whether you've reached the full dose. Patients on the full 2.4 mg dose show significantly better results than those who remain on lower doses due to tolerance issues. In STEP 1, participants who reached 2.4 mg lost an average of 2-3% more body weight than those on 1.7 mg.
• Body composition approach. Patients who combine semaglutide with resistance training and high protein intake lose predominantly fat. Those who rely on medication alone lose a higher proportion of lean mass, which can reduce metabolic rate and increase regain risk.
• Dietary patterns. Six months is enough time for dietary quality to compound. Patients who consistently eat whole foods, adequate protein, and fiber show better body composition and metabolic outcomes than those who simply eat less of the same diet.
• Alcohol consumption. Regular alcohol use (more than 3-4 drinks per week) is associated with blunted weight loss on semaglutide, based on real-world pharmacy data analyzed in Obesity (2023). Alcohol adds calories, disrupts fat metabolism, lowers inhibitions around food, and can worsen GI side effects.
• Adherence to the injection schedule. Six months means roughly 24 weekly injections. Patients who miss fewer than 2-3 doses over this period show significantly better outcomes. Setting a consistent day and time for injection helps maintain adherence.
• Concurrent medications. Medications that promote weight gain (certain antidepressants, antipsychotics, beta-blockers, insulin) can partially offset semaglutide's effects. Working with your provider to review and potentially adjust these medications can improve outcomes.

Setting Realistic Expectations at 6 Months

10-12% body weight loss is the clinical benchmark. If you've achieved this, you've matched the average from the largest, most rigorous weight loss medication trials ever conducted. This amount of weight loss is clinically significant and produces measurable health improvements.

Weight loss continues beyond 6 months. STEP trial participants continued losing weight through months 12-15 before reaching a plateau. The remaining 30-35% of total weight loss still lies ahead.

The rate of loss typically slows after month 6. This is normal and expected, not a sign that the medication has stopped working. The body reaches a new energy equilibrium as weight decreases. Weekly losses of 0.5-1 pound are typical in months 6-12, compared to 1-1.5 pounds in months 3-6.

Some patients may not respond as strongly. Approximately 15% of participants in clinical trials lost less than 5% of body weight by month 6. If you're in this group, your provider may discuss dose adjustments, switching to tirzepatide, or investigating other factors affecting your response.

Focus on the health transformation, not just pounds. A 10% weight loss reduces the risk of developing type 2 diabetes by 58%, cuts the incidence of osteoarthritis-related knee pain by 50%, and reduces cardiovascular event risk by 20% (SELECT trial data). These benefits persist as long as the weight stays off.

Tips to Maximize Your 6-Month Results

• Get bloodwork done. Month 6 is the right time for a comprehensive metabolic panel, lipid panel, and HbA1c (even if you're not diabetic). These numbers provide objective evidence of your health transformation and can be powerfully motivating.
• Reassess your calorie and protein needs. Your body is significantly lighter than it was 6 months ago. Your maintenance calorie needs have decreased. Work with your provider or a dietitian to recalculate your targets.
• Progress your strength training. If you've been doing the same routine for months, your muscles have adapted. Increase weight, add exercises, or vary your rep ranges. Progressive overload is essential for continued muscle preservation.
• Address loose skin proactively. With 25-35 pounds lost, some patients notice skin laxity. While genetics and age play a large role, hydration, collagen-supporting nutrition, and continued resistance training can help. Discuss options with your provider if this is a concern.
• Plan for the long term. Semaglutide is a long-term medication for most patients. The STEP 4 trial showed that discontinuation leads to significant weight regain. Discuss your maintenance plan with your provider.

Frequently Asked Questions

How much weight will I have lost after 6 months on semaglutide?

Clinical trial averages show 10-12% of starting body weight, which is roughly 25-35 pounds for most patients. However, results range widely. About 30% of patients exceed 15% loss, while roughly 15% lose less than 5%. Your individual result depends on dose, adherence, diet, exercise, and metabolic factors.

Is it normal for weight loss to slow down after 6 months?

Yes. The fastest weight loss typically occurs between months 3 and 6. After month 6, the rate slows as your body approaches a new metabolic equilibrium. This is a normal physiological response, not a medication failure. Weight loss generally continues through months 12-15, just at a slower pace.

Should I stop semaglutide after 6 months if I've reached my goal?

Discuss this carefully with your provider. The STEP 4 trial showed that patients who discontinued semaglutide at week 20 regained approximately two-thirds of their lost weight within 48 weeks. Most clinical guidelines recommend continued treatment for weight maintenance. Your provider can help determine the right long-term dose for your situation.

Will my insurance cover semaglutide after 6 months?

Coverage varies significantly by insurer and plan. Many plans that cover semaglutide for weight loss require documentation of continued medical necessity, which typically includes ongoing BMI criteria and evidence of response. Some plans have time limits on coverage. Form Blends can help navigate your coverage options and provide affordable compounded alternatives if insurance coverage is limited.

Can I maintain my results without the medication?

Long-term data suggests that most patients need continued pharmacotherapy to maintain weight loss. However, the habits you've built over 6 months (portion control, protein prioritization, regular exercise) provide a stronger foundation than medication alone. A reduced maintenance dose may be an option for some patients. Discuss your specific situation with your provider.

Your Six-Month Milestone Deserves Expert Support

Reaching the 6-month mark is a significant achievement. The transformation is visible, the health improvements are measurable, and the next phase of treatment is about sustaining and extending those gains. Form Blends provides physician-supervised GLP-1 therapy with ongoing monitoring to help you navigate every stage of your weight loss journey.

Get started with Form Blends today